×
High incidence of treatment-resistant hypertension in SLE comes with high mortality
https://www.mdedge.com/familymedicine/article/189287/lupus-connective-tissue-diseases/high-incidence-treatment-resistant?channel=39313
Rheumatology News; Bruce Jancin

Nov 20th, 2018 - CHICAGO – Patients with systemic lupus erythematosus (SLE) have an incidence of treatment-resistant hypertension (TRH) twice the rate of matched controls, and all-cause mortality in affected SLE patients is sharply higher than in individuals whose SLE is not complicated by comorbid TRH, Annette Oeser reported at the annual meeting of the American College of Rheumatology. Bruce Jancin/MDedge New.

Development of reversible B-cell inhibitor XmAb5871 for SLE moves forward
https://www.mdedge.com/internalmedicine/article/189174/lupus-connective-tissue-diseases/development-reversible-b-cell?channel=39313
Sharon Worcester

Nov 19th, 2018 - CHICAGO – The novel reversible B-cell inhibitor XmAb5871 showed promise for delaying loss of improvement after steroid therapy in patients with systemic lupus erythematosus in a randomized, placebo-controlled, phase 2 study. Sharon Worcester/MDedge News Dr.

Careful follow-up is key in lupus psychosis
https://www.mdedge.com/psychiatry/article/189148/lupus-connective-tissue-diseases/careful-follow-key-lupus-psychosis?channel=39313
Nicola Garrett

Nov 18th, 2018 - Psychosis, a rare manifestation of systemic lupus erythematosus (SLE), generally appears early in the disease course. But treatment can lead to good outcomes for most patients with careful follow-up, according to a large international study.

Fear of blindness hobbles hydroxychloroquine treatment of SLE
https://www.mdedge.com/familymedicine/article/189104/lupus-connective-tissue-diseases/fear-blindness-hobbles?channel=39313
Rheumatology News; Mitchel L. Zoler

Nov 16th, 2018 - CHICAGO – The dosage of hydroxychloroquine (HCQ) for treating patients with systemic lupus erythematosus (SLE) is often overly influenced by fear that the drug could cause blindness, Michelle A. Petri, MD, said at the annual meeting of the American College of Rheumatology.

Statin use reduces disease activity in AS
https://www.healio.com/rheumatology/spondyloarthropathies/news/online/%7Bdbd64962-bbdf-47f4-af98-02bb45219ae0%7D/statin-use-reduces-disease-activity-in-as

Nov 16th, 2018 - Statin use, in combination with NSAIDs, significantly reduced disease activity among patients with ankylosing spondylitis

Tofacitinib impresses in first trial for dermatomyositis
https://www.mdedge.com/internalmedicine/article/184569/lupus-connective-tissue-diseases/tofacitinib-impresses-first-trial?channel=39313
Bruce Jancin

Nov 14th, 2018 - CHICAGO – Oral tofacitinib demonstrated strong clinical efficacy and good safety in the first-ever formal study of a Janus kinase inhibitor in patients with active, treatment-resistant dermatomyositis, Julie J. Paik, MD, reported at the annual meeting of the American College of Rheumatology.

Scleroderma SCOT trial findings hold similar in lung disease
https://www.mdedge.com/internalmedicine/article/184459/lupus-connective-tissue-diseases/scleroderma-scot-trial-findings?channel=39313
Sharon Worcester

Nov 14th, 2018 - CHICAGO – Changes in quantitative lung CT scores for scleroderma-related interstitial lung disease independently validate the superiority of hematopoietic stem cell transplantation versus cyclophosphamide for severe systemic sclerosis, according to findings in a subset of patients from the SCOT (Scleroderma: Cyclophosphamide or Transplantation) trial. Mitchel L.

Women who experienced childhood abuse at higher risk for lupus
https://www.healio.com/rheumatology/lupus/news/online/%7B0113c480-ad23-4b0e-a852-cf084bb91f24%7D/women-who-experienced-childhood-abuse-at-higher-risk-for-lupus

Nov 14th, 2018 - Women who experienced physical or emotional abuse as a child demonstrated a significantly increased risk for incident systemic lupus

Should Children Be Allowed at Medical Meetings?
https://www.medscape.com/viewarticle/904890

Nov 13th, 2018 - At a recent meeting of the American Society for Radiation Oncology (ASTRO), Emma Holliday, MD, and her baby boy Micah were turned away from a poster session at which she was due to present novel research related to proton therapy for anal cancer. Her arrangements for off-site childcare had fallen through. When Holliday tweeted at the surprise ejection, ASTRO quickly responded, tweeting, "safety...

Rituximab shines in pediatric vasculitis
https://www.mdedge.com/pediatrics/article/184423/lupus-connective-tissue-diseases/rituximab-shines-pediatric-vasculitis
Bruce Jancin

Nov 13th, 2018 - CHICAGO – Rituximab demonstrated a high degree of effectiveness with no safety surprises in the first-ever major clinical trial of the potent B-cell inhibitor conducted in pediatric patients with newly diagnosed or relapsing granulomatosis with polyangiitis or microscopic polyangiitis, Jennifer Cooper, MD, PharmD, said at the annual meeting of the American College of Rheumatology. Bruce Jancin/.

Draft criteria for large-vessel vasculitis support key role for imaging
https://www.healio.com/rheumatology/vasculitis-and-giant-cell-arteritis/news/online/%7Bc31f1feb-1147-4018-a087-79513a34caa3%7D/draft-criteria-for-large-vessel-vasculitis-support-key-role-for-imaging

Nov 13th, 2018 - Advanced vascular imaging is expected to play an increasingly important role in the diagnosis and management of large-vessel vasculitis, according to a draft of the American College of Rheumatology/EULAR classification criteria for the condition.